Growacet took a trip to Toronto for the Bloom Burton conference and gleamed some interesting tidbits re: Zenith. Here's his post from the other board and I copied the Zenith releated paragraph below.

"I asked about Zenith....and he went on at length about trials, speaking glowingly.  I didn't focus in on the details because I don't own any Zenith shares.  He left me with the impression that Zenith is going to be bought out in the next few months, like 2 or 3.....also about a publication that's forthecoming that will be very positive.  I asked him if this publication would make any mention of Resverlogix, he said that it would not, but that 'we will'. He also inferred that with a buy out that Zenith investors would be getting a nice bonus, or words to that effect and that he expected some of that money to flow towards investment in Resverlogix."

1) Publication. Are they preparing a publication or has it been submitted? If submitted, how far along the peer review process. Accepted for publication yet? Once submitted, it can sometimes take several months before reviewers' and editorial board concerns are satisfied and paper accepted for publication. If truly they were this close to publication, why did they not present at the big time AACR cancer meeting last month? There were lots of BET inhibitor presentation there, including some clinical data. To me, it seems that if they were truly close to publishing something that they'd have presented at AACR. I'd love to be proven wrong. Mark me as hopeful, but skeptical.   

2) Clinical Trial. This is my biggest sticking point. I belabored on the topic of ZEN-3694/enzalutamide vs. enzalutamide alone in a previous thread. From my understanding, all patients in Zenith's trial were previosly on Abiraterone but became resistant to it (progress on Abiraterone), and were then placed on Enzalutamide plus ZEN-3694. There was no enzalutamide only group. Based on comparisons of Zenith's data slides with the studies linked below, I am personally not convinced that Zenith has not yet proven that the combo is better than the enzalutamide alone standard of care. Again, I may have misunderstanding(s). However, I think that Zenith needs to do a much better job in their presentations to put their data in a better context relative to other studies. Just drawing a dotted line and calling it standard of care and another dotted line calling it target isn't very convincing.

Efficacy and safety of enzalutamide (ENZA) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate (Abi): A multicenter, single-arm, open-label study.

Second-Line Enzalutamide May Benefit Some mCRPC Patients

Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe

3) Buyout. This sounds premature to me based on the publicly disclosed trial data. Of course, there is more data than they are showing us. Company(s) considering a Zenith buyout would surely get access to more info than the public. Also, I don't think Zenith has done a great job in their recent presentations putting their trial data into the context of current standard of care. Perhaps I am misunderstanding things. So there's a good chance that data hidden from our view and better communication of data/context make this an attractive buyout. Again, hopeful but skeptical.

GAC/Led, thanks again for attending and sharing this info! As you all know, I am long on Zenith/Resverlogix but I am also very critical. So if anyone from Zenith is reading this, I hope you can take this as contructive criticism for improving your future communications/presentations.

BearDownAZ